No Data
No Data
Zhejiang Pharmaceutical (600216.SH): No plans to develop or sell weight loss drugs
Gelonghui, May 10 丨 Zhejiang Pharmaceutical (600216.SH) said on the investor interactive platform that the company currently has no plans to develop or sell weight loss drugs.
Zhejiang Pharmaceutical (600216.SH): Net profit of 110 million yuan in the first quarter decreased by 3.44% year on year
On April 25, Ge Longhui (600216.SH) released its first quarter report. Operating revenue was 2,249 million yuan, up 12.01% year on year, net profit of 110 million yuan, down 3.44% year on year, after deducting non-net profit of 106 million yuan, up 8.07% year on year, with basic earnings per share of 0.11 yuan.
Zhejiang Pharmaceutical (600216.SH): Currently, the company's NMN products are only exported and sold to some overseas countries or regions that allow the product to be sold as a health product
Gelonghui, March 29丨Zhejiang Pharmaceutical (600216.SH) said on the investor interactive platform that NMN products cannot be registered and sold as pharmaceuticals or health products under current domestic regulations. Currently, the company's NMN products are only exported and sold to some overseas countries or regions that allow the product to be sold as health products. This business is an export/cross-border business being cultivated by the company's health products sector, and sales volume in 2023 will not be significant.
Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Zhejiang Medicine (SHSE:600216) has had a rough three months with its share price down 16%. But if you pay close attention, you might find that its key financial indicators look quite decent, which
The Three-year Shareholder Returns and Company Earnings Persist Lower as Zhejiang Medicine (SHSE:600216) Stock Falls a Further 4.0% in Past Week
For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you try your hand at stock picking, your risk returning less than the market. We reg
Zhejiang Medicine Co., Ltd. (SHSE:600216) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 24.3x Zhejiang Medicine Co., Ltd. (SHSE:600216) may be sending bullish signals at the moment, given that almost half of all companies in China have P/E rat
No Data